<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600977</url>
  </required_header>
  <id_info>
    <org_study_id>GOELAL LALA SA1</org_study_id>
    <secondary_id>U01-AA1234-01</secondary_id>
    <nct_id>NCT00600977</nct_id>
  </id_info>
  <brief_title>Liposomal Anthracyclin in the Treatment of Elderly ALL</brief_title>
  <official_title>A Multicentric Phase II-III Randomized Study Safety of Intraveinous Liposomal Pegylated Doxorubicin Versus Continuous Infusion of Doxorubicin During Induction Treatment of Acute Lymphoblastic Leukemia in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II multicentric study comparing VAD regimen with continuous infusion over 96 hours of
      doxorubicin, vincristine and dexamethasone to a 90 minutes infusion of equivalent doses of
      Dox li-PEG, bolus infusion of vincristine and dexamethasone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients aged 55 years or over will be assessed for response to steroids from day -7 to day 0
      During steroid therapy, Ph status will be determinated : patients with Ph+ ve ALL will be
      treated according to the another French Protocol while patients with Ph-ve ALL will be
      included in the &quot;caelyx&quot; protocol and randomly allocated to induction with VAD or with
      vadox-li-Peg (caelyx).

      A second course of induction therapy with VAD+ cyclophosphamide of Vadox-li-peg+
      cyclophosphamide(according to the initial randomization arm) will then be given to all
      patients.

      Consolidation therapy included 2 courses of vad or of vadox-li-Peg , according to the initial
      random allocation, followed by two courses of cytarabine,cyclophosphamide and thioguanine.

      During induction and consolidation therapy, doxorubicin and liposomal pegylated doxorubicin
      pharmacokinetics will be assessed in all patients.

      Treatment of occult CNS invasion includes skull radiotherapy and 6 intrathecal
      injections(steroÏds+methotrexate) A two years maintenance course with 6 mercaptopurine and
      methotrexate will then be offered to all patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients alive by day 113 ( last injection of anthracycline ) and having received a full course of induction/consolidation therapy</measure>
    <time_frame>113 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematological and cutaneous adverse evnts of both types of chemotherapy</measure>
    <time_frame>113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance to chemotherapy</measure>
    <time_frame>113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rates</measure>
    <time_frame>113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free and overall survival</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economical study</measure>
    <time_frame>113 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>doxorubicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicine pegylated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicine pegylated 40 MG/M² J1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicine</intervention_name>
    <description>9mg/m² J1 J4 2 COURSES</description>
    <arm_group_label>doxorubicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicine pegylated</intervention_name>
    <description>40 MG/M² J1 2 courses</description>
    <arm_group_label>Doxorubicine pegylated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  55 years of age and older

          -  ECOG performance &lt;/=2 or &gt;/=3

          -  VIH negative

          -  Absence of previous ALL treatment

          -  Informed consent signed

          -  SGPT and Bilirubin &lt; 4x upper limit of normal

          -  Normal creatinine for age

          -  cardiac state compatible with anthacyclin

        Exclusion Criteria:

          -  ALL with Philadelphia Chromosome

          -  ALL3

          -  CML blasts crisis

          -  Cardiac insufficiency and/ or left ventricular ejection fraction &lt; 50%

          -  Evolutive infection

          -  Presence of other evolutifs cancer or ongoing treatment

               -  mental status incompatible with inform consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathilde HUNAULT BERGER, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional university hospital</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>June 25, 2008</last_update_submitted>
  <last_update_submitted_qc>June 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2008</last_update_posted>
  <keyword>ALL</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Pharmacokinetics of doxorubicin (pegylated or not)</keyword>
  <keyword>elderly ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

